To be screened or not to be screened Modeling the consequences of PSA screening for the individual

British Journal of Cancer

Volumn 107, Issue 5, 2012, Pages 778-784

  Wever, E M ^a   Hugosson, J ^b   Heijnsdijk, E A M ^a   Bangma, C H ^a   Draisma, G ^a   De Koning, H J ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b SAHLGRENSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

life expectancy; prostate cancer; screening; utility

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER SCREENING; CLINICAL DECISION MAKING; CONTROLLED STUDY; DISEASE SIMULATION; HEALTH CARE UTILIZATION; HUMAN; LIFE EXPECTANCY; MAJOR CLINICAL STUDY; MALE; MICROSIMULATION MODEL; PRIORITY JOURNAL; PROSTATE CANCER; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE;

AGED; COHORT STUDIES; EARLY DETECTION OF CANCER; HUMANS; LIFE EXPECTANCY; MALE; MIDDLE AGED; MODELS, STATISTICAL; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; QUALITY OF LIFE; SURVIVAL RATE;

EID: 84865438215     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2012.317     Document Type: Article

References (31)

1. Albertsen PC, Hanley JA, Fine J (2005) 20-year outcomes following conservative management of clinically localized prostate cancer. JAMA 293: 2095-2101 (Pubitemid 40617061)
2. Albertsen PC, Moore DF, Shih W, Lin Y, Li H, Lu-Yao GL (2011) Impact of comorbidity on survival among men with localized prostate cancer. J Clin Oncol 29: 1335-1341
3. Bill-Axelson A, Holmberg L, Ruutu M, Garmo H, Stark JR, Busch C, Nordling S, Haggman M, Andersson SO, Bratell S, Spangberg A, Palmgren J, Steineck G, Adami HO, Johansson JE (2011) Radical prostatectomy versus watchful waiting in early prostate cancer. N Engl J Med 364: 1708-1717
4. Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Stranne J, Hugosson J (2011) The excess burden of side-effects from treatment in men allocated to screening for prostate cancer. The Goteborg randomised population-based prostate cancer screening trial. Eur J Cancer 47: 545-553
5. CBS (2010) Centrale Bureau van Statistieken. http://statline.cbs.nl/ StatWeb/publication/?VW=T&DM=SLNL&PA=03799&D1=291&D2=0&D3= 0&D4=1-9&HD=120201-1423&HDR=T&STB=G1,G2,G3&CHARTTYPE=1 (accessed 1 February 2012)
6. Dale W, Basu A, Elstein A, Meltzer D (2008) Predicting utility ratings for joint health States from single health States in prostate cancer: empirical testing of 3 alternative theories. Med Decis Making 28: 102-112
7. Draisma G, Boer R, Otto SJ, van der Cruijsen IW, Damhuis RA, Schroder FH, de Koning HJ (2003) Lead times and overdetection due to prostate-specific antigen screening: estimates from the European Randomized Study of Screening for Prostate Cancer. J Natl Cancer Inst 95: 868-878 (Pubitemid 36833878)
8. Draisma G, Postma R, Schroder FH, van der Kwast TH, de Koning HJ (2006) Gleason score, age and screening: modeling dedifferentiation in prostate cancer. Int J Cancer 119: 2366-2371 (Pubitemid 44546957)
9. Essink-Bot ML, Korfage IJ, De Koning HJ (2003) Including the quality-of-life effects in the evaluation of prostate cancer screening: expert opinions revisited? BJU Int 92(Suppl 2): 101-105 (Pubitemid 38091151)
10. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin D (2010) GLOBOCAN 2008, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 International Agency for Research on Cancer. http://globocan.iarc.fr (accessed on 28 December 2011). Lyon: France
11. Heidenreich A, Bellmunt J, Bolla M, Joniau S, Mason M, Matveev V, Mottet N, Schmid HP, van der Kwast T, Wiegel T, Zattoni F (2011) EAU guidelines on prostate cancer. Part 1: screening, diagnosis, and treatment of clinically localised disease. Eur Urol 59: 61-71
12. Heijnsdijk EA, der Kinderen A, Wever EM, Draisma G, Roobol MJ, de Koning HJ (2009) Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer 101: 1833-1838
13. Hugosson J, Aus G, Lilja H, Lodding P, Pihl CG (2004) Results of a randomized, population-based study of biennial screening using serum prostate-specific antigen measurement to detect prostate carcinoma. Cancer 100: 1397-1405 (Pubitemid 38366842)
14. Hugosson J, Carlsson S, Aus G, Bergdahl S, Khatami A, Lodding P, Pihl CG, Stranne J, Holmberg E, Lilja H (2010) Mortality results from the Goteborg randomised population-based prostate-cancer screening trial. Lancet Oncol 11: 725-732
15. Korfage IJ, Essink-Bot ML, Borsboom GJ, Madalinska JB, Kirkels WJ, Habbema JD, Schroder FH, de Koning HJ (2005) Five-year follow-up of health-related quality of life after primary treatment of localized prostate cancer. Int J Cancer 116: 291-296 (Pubitemid 40967268)
16. Korfage IJ, Hak T, de Koning HJ, Essink-Bot ML (2006) Patients' perceptions of the side-effects of prostate cancer treatment-a qualitative interview study. Soc Sci Med 63: 911-919
17. Lim LS, Sherin K (2008) Screening for prostate cancer in US men ACPM position statement on preventive practice. Am J Prev Med 34: 164-170
18. Parkin DM, Whelan SL, Ferlay J, Raymond L, Young J (1997) Cancer Incidence in Five Continents Vol. VII. IARC Scientific Publications, No. 143 Vol. 5IARC: Lyon
19. Potosky AL, Legler J, Albertsen PC, Stanford JL, Gilliland FD, Hamilton AS, Eley JW, Stephenson RA, Harlan LC (2000) Health outcomes after prostatectomy or radiotherapy for prostate cancer: results from the Prostate Cancer Outcomes Study. J Natl Cancer Inst 92: 1582-1592
20. Schroder FH, Hugosson J, Roobol MJ, Tammela TL, Ciatto S, Nelen V, Kwiatkowski M, Lujan M, Lilja H, Zappa M, Denis LJ, Recker F, Berenguer A, Maattanen L, Bangma CH, Aus G, Villers A, Rebillard X, van der Kwast T, Blijenberg BG, Moss SM, de Koning HJ, Auvinen A (2009) Screening and prostate-cancer mortality in a randomized European study. New Engl J Med 360: 1320-1328
21. SEER (2010) Cancer Statistics Review 1975-2007. National Cancer Institute: Bethesda. http://seer.cancer.gov (accessed September 2011)
22. Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW (2010) Cancer screening in the United States, 2010: a review of current American Cancer Society guidelines and issues in cancer screening. CA Cancer J Clin 60: 99-119
23. Spapen SJ, Damhuis RA, Kirkels WJ (2000) Trends in the curative treatment of localized prostate cancer after the introduction of prostate-specific antigen: data from the Rotterdam Cancer Registry. BJU Int 85: 474-480 (Pubitemid 30142624)
24. Steineck G, Helgesen F, Adolfsson J, Dickman PW, Johansson JE, Norlen BJ, Holmberg L (2002) Quality of life after radical prostatectomy or watchful waiting. N Engl J Med 347: 790-796 (Pubitemid 34988337)
25. Stewart ST, Lenert L, Bhatnagar V, Kaplan RM (2005) Utilities for prostate cancer health states in men aged 60 and older. Med Care 43: 347-355 (Pubitemid 40515624)
26. The National Board of Health and Welfare (2009) Official Statistics of Sweden. Causes of death 2007. http://www.socialstyrelsen.se/publikationer2009/ dodsorsaker2007 (accessed 29 April 2011)
27. Visser O, Coeberg JW, Schouten LJ (1994) Incidence of cancer in the Netherlands, 1991. Utrecht (The Netherlands): The Netherlands Cancer Registry 13: 45
28. Welch HG, Albertsen PC (2009) Prostate cancer diagnosis and treatment after the introduction of prostate-specific antigen screening: 1986-2005. J Natl Cancer Inst 101: 1325-1329
29. Wever EM, Draisma G, Heijnsdijk EA, de Koning HJ (2011) How does early detection by screening affect disease progression?: modeling estimated benefits in prostate cancer screening. Med Decis Making 31: 550-558
30. Wever EM, Draisma G, Heijnsdijk EA, Roobol MJ, Boer R, Otto SJ, de Koning HJ (2010) Prostate-specific antigen screening in the United States vs in the European Randomized Study of Screening for Prostate Cancer-Rotterdam. J Natl Cancer Inst 102: 352-355
31. Wolf AM, Wender RC, Etzioni RB, Thompson IM, D'Amico AV, Volk RJ, Brooks DD, Dash C, Guessous I, Andrews K, DeSantis C, Smith RA (2010) American Cancer Society guideline for the early detection of prostate cancer: update 2010. CA Cancer J Clin 60: 70-98